Cell-free DNA as biomarker for sepsis by integration of microbial and host information

Q Jing, CHC Leung, AR Wu - Clinical Chemistry, 2022 - academic.oup.com
Q Jing, CHC Leung, AR Wu
Clinical Chemistry, 2022academic.oup.com
Abstract Background Cell-free DNA (cfDNA) is emerging as a biomarker for sepsis. Previous
studies have been focused mainly on identifying blood infections or simply quantifying
cfDNA. We propose that by characterizing multifaceted unexplored components, cfDNA
could be more informative for assessing this complex syndrome. Methods We explored
multiple aspects of cfDNA in septic and nonseptic intensive care unit (ICU) patients by
metagenomic sequencing, with longitudinal measurement and integrative assessment of …
Background
Cell-free DNA (cfDNA) is emerging as a biomarker for sepsis. Previous studies have been focused mainly on identifying blood infections or simply quantifying cfDNA. We propose that by characterizing multifaceted unexplored components, cfDNA could be more informative for assessing this complex syndrome.
Methods
We explored multiple aspects of cfDNA in septic and nonseptic intensive care unit (ICU) patients by metagenomic sequencing, with longitudinal measurement and integrative assessment of plasma cfDNA quantity, human cfDNA fragmentation patterns, infecting pathogens, and overall microbial composition.
Results
Septic patients had significantly increased cfDNA quantity and altered human cfDNA fragmentation pattern. Moreover, human cfDNA fragments appeared to comprise information about cellular oxidative stress and could indicate disease severity. Metagenomic sequencing was more sensitive than blood culture in detecting bacterial infections and allowed for simultaneous detection of viral pathogens. We found differences in microbial composition between septic and nonseptic patients and between survivors and nonsurvivors by 28-day mortality, both on the first day of ICU admission and across the study period. By integrating all the information into a machine learning model, we achieved improved performance in identifying sepsis and prediction of clinical outcome for ICU patients with areas under the curve of 0.992 (95% CI 0.969–1.000) and 0.802 (95% CI 0.605–0.999), respectively.
Conclusions
We were able to diagnose sepsis and predict mortality as soon as the first day of ICU admission by integrating multifaceted cfDNA information obtained in a single metagenomic assay; this approach could provide important advantages for clinical management and for improving outcomes in ICU patients.
Oxford University Press